Can You Take Mushroom Supplements During Chemotherapy? Safety Lessons From a 2026 Review

By Jimmy Daoutis, Founder of AdvancedMycoTech · Last updated: April 2026

Quick summary: If you are receiving chemotherapy, do not start turkey tail, reishi, maitake, shiitake, cordyceps, chaga, or any mushroom supplement without your oncology team’s approval. A 2026 Frontiers review describes medicinal mushrooms as potential supportive adjuncts—not cancer treatments—and emphasizes standardized preparations, product variability, and clinician coordination, especially for people using immunosuppressive therapy, anticoagulants, or chemotherapy drugs with narrow therapeutic windows.

Can You Take Mushroom Supplements During Chemotherapy?

Maybe, but only with your oncology team involved. That is the safest, most honest answer.

A 2026 review in Frontiers in Cancer Control and Society examined medicinal mushrooms as supportive adjuncts during chemotherapy. The review discusses species and compounds such as turkey tail, shiitake-derived lentinan, maitake, reishi, cordyceps, oyster mushrooms, and other medicinal fungi. Its overall conclusion is cautious: medicinal mushrooms should be viewed as supportive interventions, not cytotoxic cancer treatments or replacements for chemotherapy.

That distinction matters. People often search for “mushrooms for cancer” and find exaggerated claims, supplement marketing, or anecdotal stories. AMT’s position is stricter: mushroom supplements may have legitimate immune-supportive and tolerability-related research signals, but cancer care is high-risk medicine. No supplement should be added during chemotherapy without clinician review.

Evidence strength: Moderate for safety framing, limited-to-emerging for many specific use cases — the Frontiers paper is a peer-reviewed narrative review, not a new randomized trial. Source: Haklai, 2026, Frontiers in Cancer Control and Society.

What the 2026 Frontiers Review Actually Says

The review’s abstract states that medicinal mushrooms are increasingly investigated in oncology as supportive care agents. It focuses on immunological modulation, treatment tolerability, safety, and integration with chemotherapy. The species discussed include Trametes versicolor (turkey tail), Lentinula edodes (shiitake), Grifola frondosa (maitake), Ganoderma lucidum (reishi), cordyceps species, pleurotus species, and selected additional fungi.

The review reports that polysaccharide-rich mushroom extracts can interact with innate immune receptors such as Dectin-1 and complement receptor 3, with downstream effects on natural killer cell activity, antigen presentation, and Th1-associated immune responses. It also describes favorable trends in immune preservation, myelosuppression severity, gastrointestinal and systemic inflammatory effects, and patient-reported quality of life when selected preparations are used adjunctively.

But the same review is clear about limits. It says the evidence is strongest for specific compounds such as PSK and lentinan, and that more high-quality randomized trials and standardized formulations are needed before the role of medicinal mushrooms in evidence-based integrative oncology can be defined confidently.

The Practical Translation

For patients and caregivers, the review does not mean “take any mushroom supplement during chemo.” It means the field is medically plausible and clinically interesting, but the responsible path is coordinated care, standardized products, and careful risk review.

For broader background on one of the best-studied species, see our turkey tail benefits evidence review. For safety-specific details, start with turkey tail side effects before considering any product.

The Biggest Safety Issue: Supplements Are Not All the Same

The Frontiers review highlights a problem AMT sees across the mushroom category: product variability. In its integration section, the review recommends standardized preparations with documented composition and notes that variability between commercial products is substantial. It also points to beta-glucan assays and contaminant testing as practical quality signals.

This is especially important in chemotherapy because the stakes are higher. A low-quality supplement is not just a waste of money. It may introduce uncertainty into a treatment plan where blood counts, liver enzymes, drug metabolism, bleeding risk, immune response, and infection risk may already be under close medical monitoring.

“Mushroom supplement” is also too broad a category. A turkey tail PSK/PSP extract, a reishi dual extract, a chaga powder, a cordyceps product, and a multi-mushroom blend can have different compounds, doses, contaminants, immune effects, and interaction concerns. A clinical signal for one standardized extract does not validate every retail product with the same mushroom name on the label.

What to Look For Before Even Asking Your Doctor

Species listed clearly: not just “mushroom complex.”
Mushroom part disclosed: fruiting body, mycelium, or both.
Extraction method stated: hot water, alcohol, dual extract, or powder.
Beta-glucan testing: ideally actual beta-glucans, not just total polysaccharides.
Contaminant testing: heavy metals, microbes, pesticides, and adulterants.
No cancer-cure language: aggressive treatment claims are a red flag.

For a deeper quality framework, read Beta-Glucans in Mushroom Supplements and our analysis of the beta-glucan quality gap.

Who Needs Extra Caution?

The review specifically advises caution for patients receiving immunosuppressive therapy, anticoagulants, or chemotherapy agents with narrow therapeutic indices. It also says people with known fungi allergies or autoimmune disorders should be monitored carefully when considering immunomodulatory mushroom extracts.

That is the key patient-safety takeaway. Mushroom extracts are often described as “natural,” but natural does not mean automatically safe in oncology. Some mushroom compounds are studied precisely because they can affect immune signaling. That may be useful in a supervised setting, but it can also be a reason for caution if someone is immunosuppressed, receiving immune-modulating cancer therapy, taking blood thinners, or managing autoimmune disease.

Bring These Questions to Your Oncology Team

Is this supplement appropriate with my exact chemotherapy regimen?
Could it affect blood counts, liver enzymes, bleeding risk, or immune response?
Should I avoid it near infusion days?
Are there concerns with my anticoagulants, immunosuppressants, steroids, targeted therapy, or immunotherapy?
What lab markers should be monitored if I use it?
Which dose and product format, if any, matches actual clinical evidence?

Do not rely on a supplement company’s customer support team for this decision. The right person to ask is the clinician managing your cancer treatment.

Turkey Tail, Reishi, Maitake, Shiitake, Cordyceps, and Chaga: Different Risk Profiles

The review groups multiple medicinal mushrooms under a broad supportive-care discussion, but consumers should not treat them as interchangeable.

Turkey Tail

Turkey tail is the most commercially familiar mushroom in cancer-adjacent supplement conversations. The stronger evidence base usually involves standardized compounds such as PSK and PSP, not every turkey tail capsule sold online. If someone is undergoing cancer care, the question is not “is turkey tail popular?” It is whether the exact extract, dose, and treatment context have been reviewed by the oncology team.

Reishi

Reishi is commonly used for sleep, stress, and immune support, but it also appears in safety discussions because of possible bleeding-risk concerns and immune-modulating effects. If you use anticoagulants or have surgery, low platelets, or chemotherapy-related bleeding concerns, reishi deserves extra caution. See our reishi side effects guide for a fuller safety review.

Cordyceps

Cordyceps is often marketed for energy and exercise performance, but cancer-care use is a different question. People should be especially careful not to extrapolate from athletic or general wellness research to chemotherapy settings. Our cordyceps side effects guide covers general safety considerations.

Chaga

Chaga can be high in oxalates, and product quality varies widely. For anyone with kidney issues, complex medications, or cancer-treatment-related metabolic stress, chaga should not be treated casually. Start with our chaga side effects review before considering it.

What This Does Not Mean

This review does not mean mushrooms cure cancer. It does not mean mushroom supplements can replace chemotherapy, radiation, surgery, immunotherapy, or targeted therapy. It does not mean a retail “immune blend” is equivalent to PSK, lentinan, or any standardized extract used in clinical research.

It also does not mean AMT recommends mushroom supplements for every person in cancer care. The safest article we can publish on this topic is not a product pitch. It is a decision framework: verify the evidence, identify the product, bring it to your oncology team, and avoid anything that makes disease-treatment claims.

There is a place for evidence-based integrative oncology. There is also a serious risk of overclaiming. The difference is whether the supplement is used as a clinician-supervised supportive adjunct or marketed as an alternative cancer therapy. AMT rejects the second path.

Evidence Strength Assessment

Medicinal mushrooms as supportive adjuncts during chemotherapy: Emerging to moderate — Frontiers review summarizes clinical studies, reviews, and meta-analyses, but much of the evidence is heterogeneous.
PSK and lentinan as better-supported compounds: Moderate — the review identifies these as stronger evidence areas compared with many broader retail products.
Commercial mushroom supplement generalization: Limited — substantial product variability means evidence for one standardized preparation does not validate all products.
Safety when appropriately used: Promising but context-dependent — standardized preparations may have favorable safety profiles, but oncology patients require clinician coordination.
Drug interaction certainty: Limited — the review advises caution for immunosuppressive therapy, anticoagulants, and narrow-therapeutic-index chemotherapy agents, but interaction risk depends on the patient, drug, dose, and product.

Safety-first rule

If you are in active cancer treatment, ask your oncology team before using any mushroom supplement. Bring the exact product label, dose, ingredients, and third-party testing information.

Review Mushroom Supplement Quality Signals →

FAQ

Can mushroom supplements replace chemotherapy?

No. The 2026 Frontiers review describes medicinal mushrooms as supportive adjuncts, not cytotoxic cancer treatments. They should not replace chemotherapy, radiation, surgery, immunotherapy, targeted therapy, or any prescribed cancer treatment.

Which mushroom has the best evidence in cancer care?

The review identifies stronger evidence for specific compounds such as PSK and lentinan. That does not mean every turkey tail or shiitake supplement is equivalent. The exact extract, dose, standardization, and clinical context matter.

Should I take turkey tail during chemotherapy?

Do not start turkey tail during chemotherapy without your oncology team’s approval. Turkey tail is one of the more studied medicinal mushrooms, but product quality varies and your treatment regimen, blood counts, medications, and immune status matter.

Are mushroom supplements safe with blood thinners?

Do not assume they are safe. The Frontiers review specifically advises caution for people receiving anticoagulants. If you take blood thinners or have low platelets, bleeding risk, surgery plans, or chemotherapy-related blood-count changes, ask your clinician before using mushroom supplements.

What should I avoid when shopping for mushroom supplements during cancer care?

Avoid products that claim to cure, treat, shrink, or prevent cancer. Also avoid vague blends, undisclosed mushroom species, missing dose information, no contaminant testing, no beta-glucan data, and companies that encourage you to ignore your oncology team.

Can You Take Mushroom Supplements During Chemotherapy? Safety Lessons From a 2026 Review